BARDA Orders 500,000 More Smallpox Vaccine Doses From Bavarian Nordic Against Monkeypox

As increased cases of monkeypox are being reported in the United States, the U.S. Biomedical Advanced Research and Development Authority (BARDA) has ordered an additional 500,000 additional doses of Bavarian Nordic’s Jynneos smallpox and monkeypox vaccine.

BARDA previously ordered 1.4 million doses of Jynneos, which were supplied in 2020, making the total of doses available in the U.S. almost two million doses.

Jynneos is a traditional vaccine that uses a live, nonreplicating copy of the smallpox virus to generate antibodies that protect against infection. It is the only FDA-approved vaccine against monkeypox.